340B Drug Pricing Program
Join the AHA 340B Advocacy Alliance on July 8 at 3 p.m. ET for the latest updates on the 340B Drug Pricing Program and opportunities to engage directly with AHA 340B team members.
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a legislative discussion draft that would make several changes to the 340B Drug Pricing Program.
HRSA seeks input on 340B Rebate Model.
The AHA today issued a statement denouncing unprecedented actions taken by Eli Lilly to deny 340B Drug Pricing Program discounts to certain 340B hospitals that do not meet its unilateral data requirements.
AHA can confirm that Eli Lilly has taken the extraordinary action of denying 340B discounts. Congress should immediately use its oversight authority and demand HHS take a position on drug companies’ attempts to hijack the 340B program through burdensome claims-data demands.
HRSA seeks input on 340B Rebate Model.
Cookeville Regional Medical Center (CRMC) is an independent, city-owned, not-for-profit, 309-bed regional referral medical center serving more than 350,000 residents across 14 counties.
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.
Eli Lilly Moves to Deny 340B Pricing Over Data Requirements; AHA Urges Federal Action
Eli Lilly will soon take the extraordinary step of denying 340B discounts under its unlawful claims data policy. This decision will undoubtedly harm America’s most vulnerable patients and communities, forcing hospitals to divert resources away from care and towards onerous and expensive…